Nature Reviews Clinical Oncology

Article	Citations
Tasadenoturev active in DIPG	1248
From little subclones grow mighty oaks	1205
An early switch in first-line therapy improves outcomes of advanced-stage G/GEJC	853
Sublobar resection is non-inferior to lobectomy in very early stage NSCLC	838
Sacituzumab govitecan plus pembrolizumab improves outcomes	775
Hodgkin lymphoma: great progress with room for improvement	686
Ecological management of the microbiota in patients with cancer	680
BCMA-directed therapy for early relapsed and/or refractory multiple myeloma	581
A new standard of care for advanced-stage urothelial carcinoma	556
First-line triplet therapy for advanced-stage PIK3CA-mutant HR+ breast cancer improves outcomes	518
Achieving control of nasopharyngeal carcinoma: the role of Epstein–Barr virus-based screening and vaccines	517
Novel ICI–TKI combination improves HCC outcomes	497
A prioritization framework for large-scale cancer screening under resource constraints: three ‘not all’ principles	482
Glucagon-like peptide 1 receptor agonists and cancer risk: the good, the bad and the unknown	476
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials	475
Current understanding and management of CAR T cell-associated toxicities	462
Quantitative PET-based biomarkers in lymphoma: getting ready for primetime	398
Gut microbiota in colorectal cancer development and therapy	361
Ponatinib superior to imatinib in Ph+ ALL	344
Mortality is similar with active monitoring	343
From ESMO 2022	330
Early MRD predicts disease recurrence and benefit from adjuvant chemotherapy in CRC	327
Sacituzumab tirumotecan improves OS in mTNBC	321
Daratumumab and missed sequencing opportunities in transplant-ineligible multiple myeloma: lessons for future trials	321
Belzutifan as a new option in pheochromocytomas and paragangliomas	318

Emerging trends in the global burden of colorectal cancer	315
Understanding and overcoming multidrug resistance in cancer	313
Humanized mouse models for immuno-oncology research	311
Personalized neoantigen mRNA vaccine mitigates melanoma recurrence	309
Minimal residual disease as a target for liquid biopsy in patients with solid tumours	303
Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC	299
Adding immune-checkpoint inhibitors to chemotherapy extends survival in endometrial cancer	279
Role of novel immunotherapy combinations in the management of advanced-stage hepatocellular carcinoma	271
Craniospinal irradiation improves leptomeningeal metastasis control	257
Zenocutuzumab shows efficacy in NRG1 fusion-positive solid tumours	254
Dose-reduction trials in oncology — aiming for less toxicity and better quality of life at lower costs	251
Vebreltinib effective in MET-amplified NSCLC	242
Ipilimumab plus nivolumab efficacious in patients with dMMR/MSI-H disease	235
Unresectable stage III non-small-cell lung cancer: state of the art and challenges	220
Improving outcomes in patients with oesophageal cancer	213
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship	207
MicroRNAs in oncology: a translational perspective in the era of AI	204
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response	197
Spatial landscapes of cancers: insights and opportunities	195
Biomarkers for immunotherapy of hepatocellular carcinoma	195
Promises and pitfalls of multi-cancer early detection using liquid biopsy tests	187
Approvals in 2022: overall survival, dose optimization, new approvals and beyond	183
SHINE a light: frontline ibrutinib for MCL	168
Perioperative chemotherapy superior to preoperative chemoradiotherapy for locally advanced EAC	163
Women with clinically node negative breast cancer can safely avoid axillary surgery	162
Reply to ‘Radiomics Quality Score 2.0: what changed from version 1.0 and why it matters’	159
Domvanalimab plus zimberelimab shows promise in upper-tract cancers	158
Iza-bren shows promise in recurrent or metastatic nasopharyngeal carcinoma	144
Prospective comparisons support the use of navigational bronchoscopy	140
First-line pembrolizumab plus lenvatinib is effective in non-clear-cell RCC	132
Synergistic integration of regional and systemic therapies in uveal melanoma	131
From ESMO 2023: advances in lung cancer	131
DREAMseq of therapy for BRAF-mutant melanoma	131
Targeting chromosomal instability in patients with cancer	130
Mitigating acute chemotherapy-associated adverse events in patients with cancer	128
Circulating tumour DNA — looking beyond the blood	127
Isatuximab–VRd quadruplet shows promise in transplant-ineligible NDMM	120
Long-term outcomes following CAR T cell therapy: what we know so far	120
Multiomics STEP up in correlative analysis of response to CAR T cells	116
From the ESMO Congress 2023	113
Patritumab deruxtecan shows activity in EGFR-mutant NSCLC	111
Cadonilimab is efficacious in HER2-negative advanced-stage G/GEJ adenocarcinomas	111
Sentinel lymph node biopsy improves surgical management of cervical cancer	110
Zanubrutinib succeeds in head-to-head with ibrutinib in R/R CLL	105
FIRSTMAPPP prospectively charts the efficacy of sunitinib for phaeochromocytoma and paraganglioma	103
Author Correction: The high costs of anticancer therapies in the USA: challenges, opportunities and progress	102
Author Correction: Innovative approaches for lung cancer screening and interception	101
Claudin 18.2 as a novel therapeutic target	100
Lung cancer in patients who have never smoked — an emerging disease	97
Newly approved cancer drugs in China — innovation and clinical benefit	95

Clinical implications of T cell exhaustion for cancer immunotherapy	95
Enhancing immunotherapy with tumour-responsive nanomaterials	95
Targeted biopsy reduces detection of clinically insignificant cancer	94
T-DXd effective as second-line therapy in G/GEJ cancers	93
Second-line tarlatamab improves OS in SCLC	92
Less-frequent surveillance is noninferior to annual mammography	90
Reduced-volume radiotherapy for locally advanced NPC improves QOL without compromising efficacy	88
SERENA-6: dynamic ctDNA assessment and the future of precision cancer medicine	85
The actionable transcriptome: a framework for incorporating RNA sequencing into precision oncology	83
Translating biological insights into improved management of endometrial cancer	82
Advances in the management of metastatic gastric cancer: current strategies and emerging therapeutics	81
OS benefit with first-line datopotamab deruxtecan in advanced-stage TNBC	81
Two decades of advances in clinical oncology — lessons learned and future directions	80
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges	80
Barriers in access to oncology drugs — a global crisis	80
BrECADD raises the bar in classical Hodgkin lymphoma	74
HSCT prolongs remission of high-risk CTCLs	69
Promising OS with oncolytic virotherapy	66
Thermal ablation is safer than resection of colorectal liver lesions	66
Zanidatamab shows promise as first-line therapy for advanced-stage HER2+ GEA	63
GPRC5D-CAR T cells active in MM	61
Promise with co-administration of CAR T cells	59
Exercise as a new therapeutic modality in oncology: CHALLENGE trial refines survivorship care	59
Engineering platelets as cancer therapeutics	57
Multidisciplinary management of meningiomas in the era of precision oncology	56
Non-financial conflicts of interest	56
Efficacy of TILs confirmed	56
Cured but breathless: the growing burden of DIILD in cancer survivors	55
Nirogacestat effective in desmoid tumours	55
Nano-omics: nanotechnology-based multidimensional harvesting of the blood-circulating cancerome	54
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer	53
Tabelecleucel is effective in EBV-positive lymphoproliferative disease	53
Overdiagnosis, competing morbidity and tumour biology in older women with breast cancer: building a case for active monitoring	50
The current state of the art and future trends in RAS-targeted cancer therapies	47
Repotrectinib effective in ROS1-fusion-positive NSCLC	46
Exploiting bacteria for cancer immunotherapy	46
KN046 shows tolerability and activity in TNBC	44
Navigating approval pathways for immunotherapy in NSCLC: should criteria be revised?	43
Neoadjuvant pembrolizumab improves outcomes	40
Problematic crossovers in cancer drug trials	38
Recurrent nasopharyngeal carcinoma: hyperfractionation of IMRT improves outcomes	38
Clinical implementation of multi-cancer early detection tests: can we find a path forward?	31
The emerging roles of γδ T cells in cancer immunotherapy	31
Identification of dynamic microbiota signatures in patients with melanoma receiving ICIs: opportunities and challenges	30
Optimizing the safety of antibody–drug conjugates for patients with solid tumours	30
Venetoclax–obinutuzumab combinations are effective in fit patients with CLL	30
GPRC5D as a novel immunotherapeutic target in multiple myeloma	29
Transforming perioperative treatment of gastro-oesophageal adenocarcinoma: triumphs, setbacks and future horizons	29
Repotrectinib is a next-generation TKI for NTRK fusion-positive solid tumours	29
The changing landscape of oncology clinical trials in Latin America	29
CAR T cells induce durable remission of neuroblastoma	29
MARIPOSA demonstrates overall survival benefit from amivantamab–lazertinib	29
Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma	28
Treatment of NSCLC after chemoimmunotherapy — are we making headway?	28
Personalizing adjuvant therapy for patients with colorectal cancer	27
National value-based pricing negotiation for oncology drugs — lessons from China	27
Epcoritamab is active in large B cell lymphomas	26
PERSEUS triumphs — efficacy of daratumumab confirmed in transplant-eligible NDMM	26
Laparoscopic hemihepatectomy is safe and effective	25
Neoadjuvant chemoimmunotherapy is effective in locally advanced cervical cancer	25
Adjuvant chemotherapy improves OS in UTUC	24
Menin–KMT2A interaction inhibitor shows promise	24
Personalizing the approach to neoadjuvant therapy: a promising path to improving outcomes of resectable melanoma	24
Sacituzumab tirumotecan improves OS in EGFR TKI-resistant NSCLC	21
Author Correction: Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management	21
Laparoscopic TME is non-inferior	20
The age of foundation models	19
The microbiota in radiotherapy-induced cancer immunosurveillance	19
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia	18
Systemic induction therapy and the expanding frontier of bladder preservation in MIBC	18
Synthetic lethal strategies for the development of cancer therapeutics	18
Expanding the use of T-DXd in metastatic HR-positive breast cancer: where are we now?	16
Platinum-ineligible: atezolizumab preferable	16
Early promising results with the novel KRASG12C inhibitor divarasib	16
HER2-targeted therapies beyond breast cancer — an update	16
NALIRIFOX for metastatic pancreatic adenocarcinoma: hope or hype?	15
Getting the right combination to break the epigenetic code	15
Will I feel better? Raising the bar for quality of life in oncology	15
Combination neoadjuvant therapies are paving the way for bladder preservation to become the standard for selected patients	15
Precision oncology for KRASG12C-mutant colorectal cancer	14

PROTAC SERD vepdegestrant outperforms fulvestrant for advanced-stage ER+HER2− breast cancer harbouring acquired ESR1 mutations	14
The next generation of immunotherapies for lung cancers	14
Cancer mRNA vaccines: clinical advances and future opportunities	13
At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC	13
Engaging results with glofitamab in DLBCL	12
T cell dynamics with neoadjuvant immunotherapy in head and neck cancer	12
Docetaxel-based CRT improves survival in cisplatin-ineligible patients	12
Perioperative immunotherapy for renal cell carcinoma: looking beyond the data	12
Benefit from huCAR19-IL18 cells in patients with CD19+ lymphomas after CAR T cells	11
T-DXd is effective after T-DM1	11
Liquid biopsy to inform adjuvant decisions during neoadjuvant chemotherapy — a full-circle moment for nasopharyngeal cancer	11
Thermal immuno-nanomedicine in cancer	10
Leveraging extrachromosomal DNA to fine-tune trials of targeted therapy for glioblastoma: opportunities and challenges	10
Dabrafenib–trametinib moves to the first line in low-grade glioma	9
A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions	9
Hiding in plain sight: NUT carcinoma is an unrecognized subtype of squamous cell carcinoma of the lungs and head and neck	9
Towards biomarker-driven therapies for urothelial carcinoma	8
A new era for glioma therapy — targeting mutant IDH	8
A new first-line option for advanced-stage anal squamous cell carcinoma	8
Pembrolizumab plus chemoradiotherapy effective in locally advanced cervical cancer	8
HER2-directed therapy improves urothelial cancer outcomes	8
Is NETTER-2 a practice-changing trial?	8
Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma	8
Time as an unmeasured ‘dose’ in oncology: introducing time budgeting as a design principle for cancer care	8
From detection to direction: ctDNA-guided personalized therapy for muscle-invasive bladder cancer	8
Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks	7
Tailoring targeted therapies for younger women with ER-positive early-stage breast cancer	7
‘Contribution of component’ and the perioperative immune-checkpoint inhibitor precedent	7
Targeting cuproplasia and cuproptosis in cancer	7
Molecular tumour boards — current and future considerations for precision oncology	7
In what clinical settings are the MASAI trial results applicable?	7
The molecular blueprint of targeted radionuclide therapy	7
Emerging advances and future opportunities in the molecular and therapeutic landscape of anal cancer	7
SUNLIGHT illuminates the activity of bevacizumab	6
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins	6
Functional precision oncology using patient-derived assays: bridging genotype and phenotype	6
NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3	6
Synergy of EphB2 and PD-1 blockade	6
Dostarlimab effective in dMMR LARC	6
Perioperative therapy effective in high-risk HCC	6
Cultivating the microbiome to enhance cancer immunotherapy	5
Targeting the glioblastoma resection margin with locoregional nanotechnologies	5
The SONIA trial shows the power and challenges of academic research	5
Blinatumomab improves outcomes in infant ALL	5
Adjuvant S-1 extends OS in biliary tract cancers	5
Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer	5
Circulating tumour cells for early detection of clinically relevant cancer	5
Promising results with zongertinib in advanced-stage HER2-mutant NSCLC	5
Asciminib is safe and effective in patients with newly diagnosed CML	5
Neoantigen vaccines at the crossroads: lessons from AMPLIFY-201	5
Criteria for the translation of radiomics into clinically useful tests	5
Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions	5
The biology and therapeutic implications of heterogeneity in Barrett oesophagus and oesophageal adenocarcinoma	5
Transanal TME noninferior to the laparoscopic approach	5
Early promising results with addition of an ICI and an anti-angiogenic to TACE	5
Envisioning trans-inclusive and trans-specific cancer care	4
Novel combination delivers prolonged OS	4
Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach	4
Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy	4
Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer	4
Combination neoadjuvant chemotherapy improves outcomes	4
Leptomeningeal metastatic disease: new frontiers and future directions	4
From WCC 2022	4
Did ATOMIC really improve on the standard of care for mismatch repair-deficient colon cancer?	4
Clash of the titans: axi-cel versus tisa-cel for advanced-stage DLBCL	4
Are the chronological age cutoffs used in clinical oncology guidelines biologically meaningful?	4
FDA approvals in 2024: new options for patients across cancer types and therapeutic classes	4
Adjuvant nivolumab shows promise in MCC	4
Towards equitable AI in oncology	4
AI accurately identifies targetable alterations in lung cancer histological images	4
Emerging importance of HER3 in tumorigenesis and cancer therapy	3
Novel assessment of epigenetic imprinting biomarkers for the diagnosis of thyroid nodules	3
Second-line axi-cel improves overall survival	3
Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours	3
Therapeutic targeting of mismatch repair-deficient cancers	3
The global epidemiology of acute myeloid leukaemia	3
CAR T cells show superiority over standard therapies for RRMM	3
Transforming paediatric AML trials: from failing one-size-fits-all methods to precision oncology	3
Vorasidenib: a new hope or a false promise for patients with low-grade glioma?	3
Tovorafenib effective against low-grade gliomas harbouring BRAF fusions	3
Extended neoadjuvant dostarlimab provides durable benefit in resectable dMMR solid tumours	3
CABINET presents cabozantinib as a new treatment option for NETs	3
NIR-II light in clinical oncology: opportunities and challenges	3
THOR provides new data on the efficacy of erdafitinib	3
Adding perioperative durvalumab to neoadjuvant chemotherapy provides benefit in MIBC	3
The development of CAR T cells for patients with CNS malignancies	3
Spectrum, pathobiology, mechanistic insights and diagnostic challenges of post-CAR T cell therapy lymphoproliferative disorders	3
Emerging therapeutics and evolving assessment criteria for intracranial metastases in patients with oncogene-driven non-small-cell lung cancer	3
Rare molecular subtypes of lung cancer	3
Benefit with ESCAT-guided treatment	3
Radiotherapy can be omitted for older patients with low-risk disease	3
Progress in systemic therapy for advanced-stage urothelial carcinoma	3
Bemarituzumab enters the FIGHT	3
Overall survival as a primary end point in multiple myeloma trials	3
Optimizing CAR T cell therapy for solid tumours: a clinical perspective	3